Rating Change
Barclays analysts reiterated a Overweight rating on Guardant Health, Inc. (NASDAQ:GH) on July 31, 2026.
reiterateNASDAQ:GH
Barclays Reiterates Overweight Rating on Guardant Health, Inc. (GH)
Rating Change Barclays analysts reiterated a Overweight rating on Guardant Health, Inc. (NASDAQ:GH) on July 31, 2026. Market Context Guardant Health, Inc.
Market Context
Guardant Health, Inc. operates in the Healthcare sector. The stock currently trades at $161.99 with a market capitalization of $12.6B. The stock has gained 258.5% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Guardant Health, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Guardant Health, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 31, 2026 | TD Cowen | Buy | N/A |
| Jul 31, 2026 | JP Morgan | Overweight | N/A |
| Jul 31, 2026 | Mizuho | Outperform | N/A |
| Jul 31, 2026 | RBC Capital | Outperform | N/A |
| Jul 31, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View GH Stock Page
Frequently Asked Questions
What does a Overweight rating mean for GH?
A Overweight rating from Barclays reflects the analyst's outlook on Guardant Health, Inc. (NASDAQ:GH). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GH forecast page.